Neuropathic arthropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neuropathic arthropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Denosumab for Healing Bone Fractures in Diabetic Patients with Charcot Foot https://clinicaltrials.eu/trial/study-on-denosumab-for-healing-bone-fractures-in-diabetic-patients-with-charcot-foot/ Wed, 29 Apr 2026 14:58:23 +0000 https://clinicaltrials.eu/trial/study-on-denosumab-for-healing-bone-fractures-in-diabetic-patients-with-charcot-foot/ This clinical trial is focused on studying the effects of a medication called denosumab on a condition known as Charcot foot, which can occur in people with diabetes. Charcot foot is a serious complication that involves weakening of the bones in the foot, which can lead to fractures and deformities. The study aims to see if a single injection of denosumab can help improve the healing of bone fractures and reduce the need for a special type of cast used to protect the foot.

Participants in the study will receive either denosumab or a placebo through an intravenous infusion. The study will last for about nine months, during which time the participants’ foot health will be monitored using X-rays and CT scans. These scans will help doctors see how well the bones are healing. The study will also look at other factors, such as changes in foot shape and temperature, to understand the overall impact of the treatment.

The purpose of this study is to determine if denosumab can provide beneficial effects for people with Charcot foot due to diabetes. By understanding how this medication works in these patients, researchers hope to find better ways to manage and treat this challenging condition.

]]> Study on the Effectiveness of Denosumab for Treating Acute Charcot Foot in Diabetes Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-denosumab-for-treating-acute-charcot-foot-in-diabetes-patients/ Wed, 29 Apr 2026 14:27:43 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-denosumab-for-treating-acute-charcot-foot-in-diabetes-patients/ This clinical trial is focused on studying the treatment of acute Charcot foot in patients with diabetes. Acute Charcot foot, also known as Charcot neuroarthropathy, is a condition that affects the bones, joints, and soft tissues of the foot and ankle, leading to inflammation and potential deformity. The treatment being tested in this study is called Prolia, which contains the active substance denosumab. Prolia is administered as a solution for injection under the skin.

The purpose of the study is to evaluate how effective Prolia is in treating acute Charcot foot in people with diabetes. Participants in the study will receive either Prolia or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will receive injections and attend regular visits to monitor their condition. The main goal is to see how long it takes for the acute Charcot foot to heal, which is determined by a reduction in temperature difference between the affected and unaffected foot, as well as a decrease in swelling and redness. Additional assessments will include imaging tests like X-rays and MRI to observe healing progress. The study will also track any relapses or the need for further treatment. The trial is expected to continue until December 2027.

]]>